Case Fatality Rate

The case fatality rate refers to the proportion of people or animals who die from a disease to the total number of patients or animals suffering the disease within a certain period of time, which is used to describe the severity of a particular disease. 

On February 4, the NHC announced that by 24:00 of February 3, the case fatality rate of COVID-19 in China had been controlled at 2.1%, which was lower than that of SARS (with a global case fatality rate of 11%) and higher than that of H1N1 (1%-1.5%). 

On the evening of February 24, the WHO-China Joint Mission on COVID-19 announced at its news conference that, approximately 80% of laboratory confirmed patients had mild to moderate diseases, 13.8% had severe disease and 6.1% were critical, and the case fatality rate in China was 3% to 4%, 0.7% with the exception of Wuhan; and as of February 20, the median age of confirmed cases was 51, with 80% of cases aged between 30-69 years, and 78% were from Hubei.

With traditional Chinese medicine, chloroquine phosphate, convalescent plasma therapy adopted into the diagnosis and treatment guidelines, and with Favipiravir, Remdesivir and other drugs heading into the phase of clinical research, sustainable progress has been made in the treatment of COVID-19. Xu Nanping, vice minister of science and technology, said that the vaccine is currently being developed in multiple approaches, some of which have entered animal testing phases and will be submitted for clinical trials as early as late April.

病死率

病死率是指在一定時(shí)期內(nèi)，因患某種疾病死亡的人或動(dòng)物數(shù)量占患病人或動(dòng)物總數(shù)的比例，用于描述某種特定疾病的嚴(yán)重程度。2020年2月4日，國(guó)家衛(wèi)生健康委宣布，截至2月3日晚24時(shí)，新冠肺炎全國(guó)病死率控制在2.1%，病死率低于SARS（全球病死率近11%），高于甲流（1%~1.5%）。2月24日晚，中國(guó)—世界衛(wèi)生組織新冠肺炎聯(lián)合專(zhuān)家考察組在新聞發(fā)布會(huì)上表示，新冠肺炎的輕癥、重癥、危重三類(lèi)患者分別在80%、13%和6%左右，全國(guó)病死率約在3%~4%之間，除武漢之外，全國(guó)病死率為0.7%；截至2月20日，新冠肺炎確診病例平均年齡為51歲，80%的病例年齡在30歲至69歲之間，78%的病例來(lái)自于湖北。

隨著中醫(yī)藥、磷酸氯喹、恢復(fù)期血漿治療納入診療方案，法匹拉韋、瑞德西韋等藥物進(jìn)入臨床試驗(yàn)階段，新冠肺炎治療不斷取得多項(xiàng)進(jìn)展?？萍疾扛辈块L(zhǎng)徐南平表示，目前正在多路線部署疫苗研發(fā)，部分已進(jìn)入動(dòng)物試驗(yàn)階段，最快將于4月下旬申報(bào)臨床試驗(yàn)。